Public Company News

Baozun Files Annual Reports for Fiscal Year 2025

SHANGHAI, April 23, 2026 /PRNewswire/ -- Baozun Inc. (Nasdaq: BZUN and HKEX: 9991) ("Baozun," the "Company" or the "Group"), a leading brand e-commerce solution provider and digital commerce enabler in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended D...

2026-04-23 18:50 6462

So-Young International Inc. Files Its Annual Report on Form 20-F

BEIJING, April 23, 2026 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it filed its annual report on Form 20-F for the ...

2026-04-23 18:38 4525

Inovance Invests $280M in High-Power Motor Facility, Targeting Net-Zero Heavy Industry

SHENZHEN, China, April 23, 2026 /PRNewswire/ -- Inovance Technology (SZSE: 300124) held a groundbreaking ceremony for its new R&D and manufacturing base in the Jinpu New Area of Dalian, Liaoning Province. The facility is dedicated to the development and production of high-voltage permanent magnet...

2026-04-23 18:29 3464

Baozun Releases 2025 Chairman Letter

SHANGHAI, April 23, 2026 /PRNewswire/ -- Dear Shareholders: First of all, this is a letter I write to you by myself, and it's a pure human writing without any involvement of AI (though yes I use AI everyday for a lot of things). As a company,  we are ambitious to deploy AI into a lot aspects of...

2026-04-23 18:00 4328

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

BEIJING, April 23, 2026 /PRNewswire/ -- Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) ("Baidu" or the "Company"), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 3...

2026-04-23 17:00 4413

TAL Education Group Announces Unaudited Financial Results for the Fourth Fiscal Quarter and the Fiscal Year 2026

BEIJING, April 23, 2026 /PRNewswire/ -- TAL Education Group (NYSE: TAL) ("TAL" or the "Company"), a smart learning solutions provider in China, today announced its unaudited financial results for the fourth quarter and the fiscal year ended February 28, 2026. Highlights for the Fourth Quarter of...

2026-04-23 17:00 5432

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical study of its proprietary Nectin-4-targeting ADC (R&D code: 9MW2821) for the treatment of triple-ne...

2026-04-23 16:22 7006

IFS Loops launches Agent Studio

New pre-built Field Service Digital Workers for Planning, Dispatch and Knowledge Work enable service-focused businesses to rapidly mobilize agents out-the-box PALO ALTO, Calif., April 23, 2026 /PRNewswire/ -- IFS, the leading provider of Industrial AI software, today announced strong and acceler...

2026-04-23 16:17 2754

Tuniu Discloses Cash Dividend to Holders of ADSs

NANJING, China, April 23, 2026 /PRNewswire/ -- Tuniu Corporation (NASDAQ: TOUR) ("Tuniu" or the "Company"), a leading online leisure travel company in China, today disclosed that the cash dividend of US$1.197 per American depositary shares ("ADSs") will be paid to holders of ADSs of record as of ...

2026-04-23 16:00 4590

Rykadan Capital Enters into Strategic Alliance with JERDE to Create Design-Driven Property Developments Across Asia

HONG KONG, April 23, 2026 /PRNewswire/ -- Rykadan Capital Limited ("Rykadan Capital" or the "Company", together with its subsidiaries, the "Group"; SEHK: 2288), today announced a strategic alliance with Jerde Partnership ("JERDE"), the internationally recognised architecture and urban design firm...

2026-04-23 16:00 5029

CISI Overseas Wealth Management Summit Held in Hong Kong, Spotlighting New Asset Allocation Opportunities amid Global Change

HONG KONG, April 23, 2026 /PRNewswire/ -- Against the backdrop of continued repricing in global capital markets and accelerating technological change, China Industrial Securities International Financial Group Limited ("CISI", stock code: 6058.HK) successfully held in Hong Kong on April 20 the "G...

2026-04-23 15:50 5051

Ping An Releases 2025 Sustainability Report, Unveils "SIMPLE" Framework to Drive Long-Term Value Creation

HONG KONG and SHANGHAI, April 23, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or "the Group"; HKEX: 2318/82318; SSE: 601318) released its 2025 Sustainability Report, introducing for the first time its "SIMPLE" sustainability framework, which demonstrates how t...

2026-04-23 15:19 7422

Mozambique President Visits Zoomlion Smart Industrial City During China State Visit

CHANGSHA, China, April 23, 2026 /PRNewswire/ -- Mozambique's President Daniel Francisco Chapo toured the manufacturing facilities of Chinese heavy equipment maker Zoomlion on April 16, marking the first day of a weeklong state visit to China as the African nation seeks to accelerate its infrastru...

2026-04-23 15:15 5686

2026 ASCO | Mabwell to Present Latest Clinical Data on 9MW2821 Combined with Toripalimab for Urothelial Carcinoma in Oral and Poster Presentations

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that two latest clinical study results of its Nectin-4-targeting ADC 9MW2821 in combination with toripalimab for urothelial carcinoma wil...

2026-04-23 15:02 1784

WuXi Biologics Receives South Korea MFDS GMP Certification to Enable Commercial Manufacturing of Bispecific Antibody Therapeutics

WUXI, China, April 23, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that three of its manufacturing facilities in Wuxi – Drug Substance Facility 5 (MFG5), Drug Product Facility 2 (DP2), and Drug P...

2026-04-23 14:14 4327

Trinasolar Introduces Vertex N G3 Module to South Korea, Supporting High-Efficiency and Bankable Solar Deployment

SEOUL, South Korea, April 23, 2026 /PRNewswire/ -- Trinasolar, a global leader in smart solar and energy storage solutions, has introduced its latest high-power module, the Vertex N G3, to the South Korea market. The module leverages Trinasolar's advancedn-type i-TOPCon Ultra technology, deliveri...

2026-04-23 14:04 5341

MetaOptics achieves a progressive milestone in securing design/evaluation orders for its metalenses and modules from world-class customers

SINGAPORE, April 23, 2026 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) ("MetaOptics" or the "Company", and together with its subsidiaries, the "Group") is pleased to announced that it has achieved a progressive milestone in securing design/evaluation orders of its metalenses and modules from w...

2026-04-23 11:43 7068

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

SAN DIEGO, April 22, 2026 /PRNewswire/ -- Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting, held from April 17 to 22, 2026, in...

2026-04-23 11:37 4592

Yalla Group Releases 2025 ESG Report

DUBAI, UAE, April 22, 2026 /PRNewswire/ -- Yalla Group Limited ("Yalla" or the "Company") (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today published its 2025 Environmental, Social and Governance (ESG) Report. The report outline...

2026-04-23 10:30 4946

2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer

SUZHOU, China, April 23, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the results from a Phase I clinical study (JSKN016-101, NCT06592417) of its first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) JSKN016, for the treatment of HER2-negative lo...

2026-04-23 10:19 1551